Pterostilbene on Metabolic Parameters: A Randomized, Double-Blind, and Placebo-Controlled Trial
Table 1
Baseline demographics.
Characteristic
Placebo* ()
Low dose ()
Low dose + GE ()
High dose ()
Age (years)
54.40 (11.88)
53.55 (7.90)
52.95 (13.73)
53.55 (11.17)
Female
13 (65%)
15 (75%)
15 (75%)
14 (70%)
Race
Caucasian
10 (50%)
15 (75%)
15 (75%)
16 (80%)
African American
10 (50%)
5 (25%)
3 (15%)
4 (20%)
Asian
0 (0%)
0 (0%)
2 (10%)
0 (0%)
Weight (lbs)
194.66 (46.10)
185.32 (50.91)
192.76 (44.56)
181.79 (40.56)
BMI (kg/m2)
30.09 (6.30)
30.30 (8.29)
31.09 (5.86)
29.25 (6.02)
Blood pressure
SBP (mmHg)
130.20 (15.21)
125.15 (14.35)
125.40 (14.01)
128.75 (19.99)
DBP (mmHg)
80.95 (8.89)
78.70 (5.59)
78.50 (7.32)
78.95 (10.16)
Hypertensive
13 (65%)
12 (60%)
8 (40%)
11 (55%)
Cholesterol
LDL (mg/dL)
143.80 (44.03)
142.35 (29.46)
140.90 (37.03)
140.20 (27.41)
HDL (mg/dL)
53.25 (16.01)
63.30 (18.17)
56.60 (15.10)
58.25 (23.41)
Triglycerides (mg/dL)
118.45 (55.02)
109.95 (45.40)
163.90 (70.57)
124.50 (82.94)
Cholesterol medication
8 (40%)
7 (35%)
7 (35%)
7 (35%)
Statin
6 (30%)
6 (30%)
7 (35%)
6 (30%)
Smokers
0 (0%)
3 (15%)
2 (10%)
3 (15%)
ASCVD risk score (%)
6.8 (5.1)
7.5 (11.6)
7.5 (10.1)
8.6 (7.6)
Framingham 10-year risk (%)
5.70 (6.87)
5.50 (7.27)
6.40 (8.80)
5.80 (5.88)
Values are mean (SD) or (%). BMI: body mass index; LDL: low-density lipoprotein; HDL: high-density lipoprotein; TG: triglycerides; ASCVD: atherosclerotic cardiovascular disease. denote that these data are “Compared to Placebo”.
